Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer.
Background: BBO-8520 is a first-in-class, potent, selective, directly binding, orally bioavailable, covalent inhibitor of KRASG12C. It is effective against both the active GTP-bound (ON) state and the inactive GDP-bound (OFF) state of KRASG12C. BBO-8520 is being developed to treat patients with advanced cancer harboring the KRASG12C mutation. The oncogenic KRASG12C mutation results in an increased abundance of KRASG12C in the active GTP-bound (ON) state. While recent approvals of KRASG12C-targeted therapies provide a new treatment option for patients with KRASG12C-driven cancers, these agents exclusively target the GDP-bound (OFF) state of the protein, enabling the emergence of heterogeneous adaptive resistance. Thus, there is an urgent need for agents that can provide durable treatment benefit. Methods: This first-in-human, multicenter, open-label, Phase 1a/1b study evaluates the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BBO-8520 as monotherapy and in combination with pembrolizumab in subjects with advanced non-small-cell lung cancer (NSCLC) with a KRASG12C mutation. BBO-8520 is administered orally once daily, in a 21-day treatment cycle. Patients enrolled in the trial must have histologically documented locally advanced or metastatic NSCLC with a KRASG12C mutation. Patients with treated or stable brain metastases are allowed to participate in the study. During Phase 1a dose escalation, BBO-8520 will be evaluated at escalating doses as monotherapy and in combination with pembrolizumab. The primary objective of Phase 1a is to evaluate the safety and tolerability of BBO-8520 monotherapy or in combination with pembrolizumab and determine the optimal dose(s) for Phase 1b dose expansion. Patients with KRASG12C -mutant NSCLC who have received prior treatment with KRASG12C (OFF) inhibitors are allowed to participate in Phase 1a. During Phase 1b dose expansion, BBO-8520 will be evaluated as monotherapy in expansion cohorts of: (1) patients with advanced NSCLC and prior treatment with KRASG12C (OFF) inhibitors; and (2) patients with advanced NSCLC and no prior treatment with KRASG12C inhibitors. BBO-8520 will also be evaluated in combination with pembrolizumab in an expansion cohort of patients with advanced NSCLC and no prior treatment with immune checkpoint or KRASG12C inhibitors. The primary objective of Phase 1b is to verify safety and tolerability of BBO-8520 monotherapy and in combination with pembrolizumab and evaluate antitumor activity (objective response rate evaluation).
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
